Login to Your Account



ODAC supports Mylotarg comeback, EFS endpoint

By Mari Serebrov
Regulatory Editor

Tuesday, July 11, 2017

A change in dosing and support for a new endpoint could be the charm Pfizer Inc.'s Mylotarg needs to return to the U.S. market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription